Business Trends
Retatrutide Data Strengthens Eli Lilly’s Expanding Obesity Platform
Eli Lilly (LLY) shares climbed after new Phase 3 data for retatrutide showed substantial weight loss and improvements across obesity-related conditions, reinforcing the company’s broader push into cardiometabolic treatment markets.